Loading
A phase 3 trial of Capecitabine, Eribulin and Gemcitabine in HER2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06957886 by Sichuan Baili Pharmaceutical Co., Ltd., with 566 participants planned, started 2025-05-15 and due to reach its primary completion in 2027-05. Interventions recorded: BL-M07D1 and Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eribulin, SystImmune / Sichuan Biokin, Capecitabine, Gemcitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Capecitabine and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine and the tag pipeline.
Shares SystImmune / Sichuan Biokin, HER2-positive breast cancer and the tag pipeline.
Shares Eribulin, Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/